RU2019113989A - Лекарственное средство - Google Patents
Лекарственное средство Download PDFInfo
- Publication number
- RU2019113989A RU2019113989A RU2019113989A RU2019113989A RU2019113989A RU 2019113989 A RU2019113989 A RU 2019113989A RU 2019113989 A RU2019113989 A RU 2019113989A RU 2019113989 A RU2019113989 A RU 2019113989A RU 2019113989 A RU2019113989 A RU 2019113989A
- Authority
- RU
- Russia
- Prior art keywords
- derived peptide
- lag
- gpc3
- hsp70
- protein
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 30
- 239000003814 drug Substances 0.000 claims 15
- 102000017578 LAG3 Human genes 0.000 claims 12
- 101150030213 Lag3 gene Proteins 0.000 claims 12
- 101710163595 Chaperone protein DnaK Proteins 0.000 claims 11
- 102100032530 Glypican-3 Human genes 0.000 claims 11
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 claims 11
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 claims 11
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 7
- 229940126601 medicinal product Drugs 0.000 claims 7
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000003970 toll like receptor agonist Substances 0.000 claims 6
- 239000012648 POLY-ICLC Substances 0.000 claims 5
- 108020001507 fusion proteins Proteins 0.000 claims 5
- 102000037865 fusion proteins Human genes 0.000 claims 5
- 108700002563 poly ICLC Proteins 0.000 claims 5
- 229940115270 poly iclc Drugs 0.000 claims 5
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 claims 2
- 101710114827 Protein lag-3 Proteins 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 229940124122 Toll-like receptor 3 agonist Drugs 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001176—Heat shock proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464492—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/844—Liver
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (47)
1. Лекарственное средство, включающее:
агонист Toll-подобного рецептора и
белок LAG-3, его вариант или производное.
2. Лекарственное средство по п. 1 для комбинированного введения:
агониста Toll-подобного рецептора и
белка LAG-3, его варианта или производного.
3. Лекарственное средство по п. 1 или 2, где агонист Toll-подобного рецептора является агонистом Toll-подобного рецептора 3 или агонистом Toll-подобного рецептора 9.
4. Лекарственное средство по любому из пп. 1-3, где агонистом Toll-подобного рецептора является Поли-I:С или его соль.
5. Лекарственное средство по п. 4, где Поли-I:С является Поли-ICLC.
6. Лекарственное средство по любому из пп. 1-5, где белок LAG-3, его вариант или производное является слитым белком белка LAG-3 и IgG.
7. Лекарственное средство по любому из пп. 1-6, дополнительно включающее по меньшей мере один полученный из ракового антигена пептид.
8. Лекарственное средство по п. 7, где по меньшей мере один полученный из ракового антигена пептид является HSP70-производным пептидом или GРС3-производным пептидом.
9. Лекарственное средство по п. 7 или 8, включающее:
по меньшей мере один тип полученного из ракового антигена пептида, выбранный из группы, состоящей из НSР70-производного пептида и GРС3-производного пептида,
Поли-ICLC и
белок LAG-3 или слитый белок белка LAG-3 и IgG.
10. Лекарственное средство по п. 9, включающее HSP70-производный пептид, имеющий аминокислотную последовательность, представленную SEQ ID No: 7, или GРС3-производный пептид, имеющий аминокислотную последовательность, представленную SEQ ID No: 16.
11. Лекарственное средство по любому из пп. 7-10, включающее по меньшей мере два типа полученных из раковых антигенов пептидов.
12. Лекарственное средство по п. 11, включающее HSP70-производный пептид и полученный из ракового антигена пептид кроме НSР70-производного пептида.
13. Лекарственное средство по п. 11, включающее GPC3-производный пептид и полученный из ракового антигена пептид кроме GРС3-производного пептида.
14. Лекарственное средство по п. 11, включающее HSP70-производный пептид и GРС3-производный пептид.
15. Лекарственное средство по п. 14, включающее HSP70-производный пептид, имеющий аминокислотную последовательность, представленную SEQ ID No: 7, и GPC3-производный пептид, имеющий аминокислотную последовательность, представленную SEQ ID No: 16.
16. Лекарственное средство по п. 12, включающее:
HSP70-производный пептид, полученный из ракового антигена пептид кроме HSP70-производного пептида,
Поли-ICLC и
белок LAG-3 или слитый белок белка LAG-3 и IgG.
17. Лекарственное средство по п. 13, включающее:
GРС3-производный пептид, полученный из ракового антигена пептид кроме GРС3-производного пептида,
Поли-ICLC и
белок LAG-3 или слитый белок белка LAG-3 и IgG.
18. Лекарственное средство по п. 14, включающее:
HSP70-производный пептид, GРС3-производный пептид,
Поли-ICLC и
белок LAG-3 или слитый белок белка LAG-3 и IgG.
19. Лекарственное средство по п. 18, включающее:
HSP70-производный пептид, имеющий аминокислотную последовательность, представленную SEQ ID No: 7, и
GРС3-производный пептид, имеющий аминокислотную последовательность, представленную SEQ ID No: 16.
20. Лекарственное средство по любому из пп. 1-19 для применения в вакцинотерапии рака.
21. Лекарственное средство по любому из пп. 1-20, где лекарственное средство является противоопухолевым средством.
22. Адъювант, включающий:
агонист Toll-подобного рецептора и
белок LAG-3, его вариант или производное,
для применения в индукции специфичного иммунного ответа против раковой клетки.
23. Комбинация, включающая:
агонист Toll-подобного рецептора и
белок LAG-3, его вариант или производное,
для применения в индукции специфичного иммунного ответа против раковой клетки.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016200227 | 2016-10-11 | ||
JP2016-200227 | 2016-10-11 | ||
PCT/JP2017/015227 WO2018070069A1 (ja) | 2016-10-11 | 2017-04-14 | 医薬 |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2019113989A3 RU2019113989A3 (ru) | 2020-11-13 |
RU2019113989A true RU2019113989A (ru) | 2020-11-13 |
RU2759728C2 RU2759728C2 (ru) | 2021-11-17 |
Family
ID=61905333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2019113989A RU2759728C2 (ru) | 2016-10-11 | 2017-04-14 | Лекарственное средство |
Country Status (10)
Country | Link |
---|---|
US (2) | US11291718B2 (ru) |
EP (1) | EP3527216B1 (ru) |
JP (1) | JP6998880B2 (ru) |
CN (1) | CN109982711A (ru) |
AU (1) | AU2017342189B2 (ru) |
BR (1) | BR112019006075A2 (ru) |
CA (1) | CA3039033A1 (ru) |
RU (1) | RU2759728C2 (ru) |
TW (1) | TW201813664A (ru) |
WO (1) | WO2018070069A1 (ru) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202115102A (zh) * | 2015-03-09 | 2021-04-16 | 日商賽多利克公司 | 來自gpc3之胜肽、使用此胜肽之用於治療或預防癌症之醫藥組成物、免疫誘導劑、及抗原呈現細胞之製造方法 |
JP6311094B2 (ja) | 2015-04-07 | 2018-04-18 | サイトリミック株式会社 | 医薬 |
EP3527216B1 (en) | 2016-10-11 | 2024-02-14 | NEC Corporation | A medicine comprising a toll-like receptor agonist, lag-3 protein, a hsp70-derived peptide and a gpc3-derived peptide |
EP4066852A4 (en) * | 2019-11-27 | 2024-05-22 | Nec Corp | PHARMACEUTICAL COMPOSITION |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196523A (en) | 1985-01-01 | 1993-03-23 | The University Of Southern California | Control of gene expression by glucose, calcium and temperature |
JPH08151396A (ja) | 1994-11-28 | 1996-06-11 | Teijin Ltd | Hla結合性オリゴペプチド及びそれを含有する免疫調節剤 |
RS50101B (sr) * | 1996-02-24 | 2009-01-22 | Boehringer Ingelheim International Gmbh., | Farmaceutski preparati za imunomodulaciju |
EP0893507A1 (en) * | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
KR100856446B1 (ko) | 1998-12-23 | 2008-09-04 | 화이자 인크. | Ctla-4에 대한 인간 단일클론 항체 |
ES2282133T3 (es) | 1999-08-24 | 2007-10-16 | Medarex, Inc. | Anticuerpos frente a la ctla-4 humano y sus usos. |
AU2002212236A1 (en) | 2000-09-13 | 2002-03-26 | Gabriele Multhoff | An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof |
US20030171280A1 (en) | 2001-07-31 | 2003-09-11 | Soderstrom Karl Petter | Compositions and methods for modulation of immune responses |
JP4406607B2 (ja) | 2002-08-26 | 2010-02-03 | オンコセラピー・サイエンス株式会社 | ペプチド及びこれを含む医薬 |
EP2572714A1 (en) | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
FR2863890B1 (fr) | 2003-12-19 | 2006-03-24 | Aventis Pasteur | Composition immunostimulante |
CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
JP2008540625A (ja) | 2005-05-19 | 2008-11-20 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | E.coli易熱性毒素のB−サブユニット、抗原およびアジュバントを含むワクチン組成物 |
CN103242428B (zh) | 2005-08-09 | 2015-04-15 | 肿瘤疗法.科学股份有限公司 | 用于hla-a2阳性人群的来自磷脂酰肌醇蛋白聚糖-3 (gpc3)的癌症排斥抗原肽以及含有该肽的药物 |
US20100015101A1 (en) | 2006-03-28 | 2010-01-21 | Noriyuki Sato | Novel tumor antigen peptides |
RU2333767C2 (ru) | 2006-03-31 | 2008-09-20 | Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") | Вакцинные композиции, способы их применения для профилактики и лечения меланомы и генетические конструкции для получения действующих компонентов композиции |
CN101311270A (zh) * | 2006-08-18 | 2008-11-26 | 上海交通大学医学院 | 一种可诱生细胞免疫应答的真核表达载体及其疫苗 |
EP2687540A1 (en) | 2006-10-17 | 2014-01-22 | Oncotherapy Science, Inc. | Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides |
US20100137221A1 (en) | 2007-02-27 | 2010-06-03 | University Utah Research Foundation | Peptides that interact with topoisomerase i and methods thereof |
DK2170959T3 (da) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | Antistoffer mod human programmeret dødsreceptor pd-1 |
CN101801402B (zh) | 2007-07-06 | 2013-08-28 | 乌得勒支大学控股有限公司 | 炎性疾病和自身免疫疾病的治疗和预防 |
JP2010538655A (ja) | 2007-09-12 | 2010-12-16 | アナフォア インコーポレイテッド | 自己免疫疾患についてのhsp70に基づく治療 |
KR100900837B1 (ko) | 2007-12-07 | 2009-06-04 | (주)두비엘 | 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물 |
US9370558B2 (en) | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
TWI686405B (zh) | 2008-12-09 | 2020-03-01 | 建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
EA021842B1 (ru) | 2009-10-06 | 2015-09-30 | Общество С Ограниченной Ответственностью "Панацела Лабс" | Применение toll-подобного рецептора и агониста для лечения рака |
RS60033B1 (sr) | 2009-11-24 | 2020-04-30 | Medimmune Ltd | Ciljano vezujući agensi usmereni na b7-h1 |
WO2012139094A2 (en) * | 2011-04-08 | 2012-10-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of developing a vaccine using peptide-poly ic complexes |
BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
SG11201404543UA (en) * | 2012-02-02 | 2014-08-28 | California Stem Cell Inc | Pluripotent germ layer origin antigen presenting cancer vaccine |
KR20140129124A (ko) | 2012-02-07 | 2014-11-06 | 라 졸라 인스티튜트 포 앨러지 앤드 이뮤놀로지 | 티모시 그라스 알레르겐들 및 면역반응 조절을 위한 방법들 및 용도들 |
US20130217122A1 (en) | 2012-02-21 | 2013-08-22 | The Trustees Of The University Of Pennsylvania | Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library |
WO2013143026A1 (en) | 2012-03-31 | 2013-10-03 | Abmart (Shanghai) Co., Ltd | Peptide and antibody libraries and uses thereof |
TWI693073B (zh) | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對gpc3標的治療劑療法為有效之患者投與的gpc3標的治療劑 |
IN2014CH00395A (ru) * | 2013-02-05 | 2015-04-03 | Nitto Denko Corp | |
CN110448566A (zh) | 2013-03-01 | 2019-11-15 | 阿斯泰克斯制药公司 | 药物组合 |
US10682400B2 (en) | 2014-04-30 | 2020-06-16 | President And Fellows Of Harvard College | Combination vaccine devices and methods of killing cancer cells |
US10537626B2 (en) | 2014-10-07 | 2020-01-21 | Cytlimic Inc. | HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell |
TW202115102A (zh) * | 2015-03-09 | 2021-04-16 | 日商賽多利克公司 | 來自gpc3之胜肽、使用此胜肽之用於治療或預防癌症之醫藥組成物、免疫誘導劑、及抗原呈現細胞之製造方法 |
JP6311094B2 (ja) | 2015-04-07 | 2018-04-18 | サイトリミック株式会社 | 医薬 |
WO2018021400A1 (ja) | 2016-07-27 | 2018-02-01 | 国立大学法人北海道大学 | がん免疫アジュバント |
EP3527216B1 (en) | 2016-10-11 | 2024-02-14 | NEC Corporation | A medicine comprising a toll-like receptor agonist, lag-3 protein, a hsp70-derived peptide and a gpc3-derived peptide |
-
2017
- 2017-04-14 EP EP17859460.2A patent/EP3527216B1/en active Active
- 2017-04-14 CN CN201780062815.4A patent/CN109982711A/zh active Pending
- 2017-04-14 JP JP2018544679A patent/JP6998880B2/ja active Active
- 2017-04-14 BR BR112019006075A patent/BR112019006075A2/pt not_active IP Right Cessation
- 2017-04-14 RU RU2019113989A patent/RU2759728C2/ru active
- 2017-04-14 US US16/341,415 patent/US11291718B2/en active Active
- 2017-04-14 TW TW106112505A patent/TW201813664A/zh unknown
- 2017-04-14 AU AU2017342189A patent/AU2017342189B2/en active Active
- 2017-04-14 CA CA3039033A patent/CA3039033A1/en not_active Abandoned
- 2017-04-14 WO PCT/JP2017/015227 patent/WO2018070069A1/ja unknown
-
2022
- 2022-02-25 US US17/680,719 patent/US11759518B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US11759518B2 (en) | 2023-09-19 |
CA3039033A1 (en) | 2018-04-19 |
JP6998880B2 (ja) | 2022-02-10 |
EP3527216A4 (en) | 2020-04-01 |
BR112019006075A2 (pt) | 2019-06-18 |
JPWO2018070069A1 (ja) | 2019-09-26 |
EP3527216B1 (en) | 2024-02-14 |
EP3527216A1 (en) | 2019-08-21 |
AU2017342189B2 (en) | 2023-09-21 |
WO2018070069A1 (ja) | 2018-04-19 |
US20220175915A1 (en) | 2022-06-09 |
TW201813664A (zh) | 2018-04-16 |
US20200038508A1 (en) | 2020-02-06 |
RU2759728C2 (ru) | 2021-11-17 |
CN109982711A (zh) | 2019-07-05 |
RU2019113989A3 (ru) | 2020-11-13 |
US11291718B2 (en) | 2022-04-05 |
AU2017342189A1 (en) | 2019-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6820226B2 (ja) | 高齢患者におけるワクチン接種 | |
RU2019113989A (ru) | Лекарственное средство | |
TWI379839B (en) | Aβ immunogenic peptide carrier conjugates and methods of producing same | |
HRP20190799T1 (hr) | Imunocitokini na bazi il-15 i sushi domene il-15r alfa | |
CY1118373T1 (el) | Υψηλης συγκεντρωσης υγρες μορφοποιησεις anti-tnfa αντισωματος | |
ES2619077T3 (es) | Composiciones farmacéuticas que comprenden un polipéptido que comprende al menos un motivo CXXC y antígenos heterólogos y usos de las mismas | |
JP2015533376A5 (ru) | ||
RU2016122957A (ru) | Способы применения интерлейкина-10 для лечения заболеваний и расстройств | |
JP2018510215A5 (ru) | ||
JP2016519933A5 (ru) | ||
HRP20220924T1 (hr) | Imunoterapija zasnovana na pd-l1 | |
EA202090738A1 (ru) | Способ безопасного индуцирования иммунитета против rsv | |
WO2018067217A3 (en) | COMPOSITIONS COMPRISING SHORT PEPTIDES DERIVED FROM PEDF AND USES THEREOF | |
JP2018510132A5 (ru) | ||
JP2015509707A5 (ru) | ||
CA2922467A1 (en) | Oncology vaccine | |
JP2014508734A5 (ru) | ||
WO2005028505A3 (en) | Multiepitope polypeptides for cancer immunotherapy | |
JP2014502961A5 (ru) | ||
ES2565578T3 (es) | Vacunas contra el cáncer que contienen epítopos de antígeno oncofetal | |
RU2018116601A (ru) | Иммунногенный слитый белок | |
Basto et al. | Immune response profile elicited by the model antigen ovalbumin expressed in fusion with the bacterial OprI lipoprotein | |
US10597426B2 (en) | Polypeptide compound and preparation method and use thereof | |
JOP20210284A1 (ar) | الإعطاء غير المتجانس للقاحات تاو | |
RU2017134693A (ru) | Лекарственное средство |